• allogeneic bone marrow transplantation;
  • allogeneic peripheral blood stem cell transplantation;
  • autologous haematopoietic stem cell transplantation;
  • multiple myeloma

Abstract. Gahrton G. & Björkstrand B. (Departments of Medicine and Hematology, Karolinska Institutet and Huddinge University Hospital, Huddinge, Sweden). Progress in haematopoietic stem cell transplantation for multiple myeloma (Review). J Intern Med 2000; 248: 185–201.

High-dose myeloablative treatment followed by autologous haematopoietic stem cell transplantation has significantly improved survival of patients younger than 65 years of age with multiple myeloma as compared with conventional chemotherapy. However, all patients seem to relapse and molecular remissions are rare.

Results of allogeneic transplantation, still hampered by high transplant-related mortality, have improved dramatically over the last 5–6 years and this is an option for patients younger than 50–55 years old. The relapse rate is lower than with autologous transplantation and molecular remissions are frequent. Some patients are still in complete haematological remission more the 10 years following transplantation.

Autologous transplantation followed by nonmyeloablative allogeneic transplantation is on trial and may be a way to eventually cure a fraction of younger patients with multiple myeloma.